Mission Pharmacal Partners with TriLogic Pharma on Drug Delivery Platform

SAN ANTONIO, Oct 03, 2011 (BUSINESS WIRE) -- Mission Pharmacal Company announced today that it is developing a new drug delivery system utilizing technology developed by TriLogic Pharma. The delivery system will be based upon TriLogic's proprietary drug delivery platform TRI-726 and will be licensed to Mission Pharmacal for future drug development.

"Mission Pharmacal's growth over the last 60 years has been the result of good relationships with other innovative pharmaceutical companies. We look forward to working with TriLogic and its new technology," stated Terry Herring, president of Mission Pharmacal's Commercial Operations.

Jim Harwick, president of TriLogic Pharma, said, "We are excited to partner with Mission Pharmacal on the development of a new drug delivery system. We continue to be pleased with the versatility of TRI-726 and the wide range of therapeutic classes and actives that can be developed with our novel delivery platform."

About Mission Pharmacal

Mission Pharmacal is a privately held pharmaceutical company based in San Antonio. For more than 60 years, the company has been committed to meeting the unique healthcare needs of women throughout all stages of life, pediatric patients, and those persons dealing with urologic conditions. The company has a proven track record of identifying unmet healthcare needs and in developing both innovative prescription and over-the-counter products to meet those needs. Mission Pharmacal provides physicians and consumers with the highest quality pharmaceutical and dietary supplement products on the market today. The company uses only the purest and most reliable ingredients in its products. For more information about the company, visit www.missionpharmacal.com .

About TriLogic Pharma

TriLogic Pharma is a specialty pharmaceutical company working on clear solutions for innovative drug delivery. Their proprietary drug delivery platform, TRI-726, is capable of delivering a large number of actives over several hours to several days. The platform focuses on three logics of in-situ gelation, sustained-erosion and bio-resorption, and adhesion. The three logics, when combined, provide ease of use, better tolerability, and therapy compliance. TriLogic Pharma is based in Montgomery, AL. For more information visit www.trilogicpharma.com or call toll free 866-562-8042.

SOURCE: TriLogic Pharma


Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.